Table 1 General characteristics of 91 patients with neuromyelitis optica spectrum disorders
Characteristics | Total |
|---|---|
Age at onset (years), average ± SD | 36.3 ± 13.6 |
Female, n (%) | 72 (79.1) |
Afro-descendants, n (%) | 67 (73.6) |
First syndrome, n (%) | |
Optic neuritis | 19 (22.4) |
Transverse Myelitis | 28 (32.9) |
Area postrema syndrome | 5 (5.9) |
ON + TM | 18 (21.2) |
ON + TM + APS | 5 (5.9) |
ON + APS | 3 (3.5) |
TM + APS | 7 (8.2) |
EDSS, median, (interquartile) | 4 (2.62–6.50) |
AQP4-IgG + , n (%) | 55 (73.3)* |
Autoimmune disease, n (%) | 9 (10.2) |
Recurrence, n (%) | 71 (83.5) |
Number of attacks, average ± SD | 4.0 ± 3.6 |
Disease time (years), average ± SD | 7.8 ± 6.9 |
Relapse rate, average ± SD | 1.3 ± 1.6 |
Progression index, average ± SD | 2.3 ± 4.1 |
Brain MRI lesions, n (%) | 57 (75.0) |
Spinal cord MRI lesions, n (%) | 68 (90.7) |
Number of affected vertebral bodies, median, (interquartile) | 5 (3.0–7.0) |
Longitudinally extensive lesion, n (%) | 51 (78.5) |
Spinal cord lesion topography, n (%) | |
Cervical | 25 (38.5) |
Thoracic | 10 (15.4) |
Cervical and thoracic | 18 (27.7) |
Thoracic and lumbar | 2 (2.9) |
Lumbar and sacral | 1 (1.5) |
Without injury | 9 (13.8) |
Type of treatment, n (%) | |
Azathioprine and glucocorticoid | 37 (50.7) |
Azathioprine | 30 (41.1) |
Rituximab | 6 (8.2) |